Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nichola Cooper

Showing results (21-30 of 141) with videos related to

Pageof 15
Sort By:
The New England Journal of Medicine|February 11, 2011
Safety of recombinant activated factor VII in randomized clinical trialsAmit Patel, Nichola Cooper, Michael A Laffan
British Journal of Haematology|April 4, 2017
Haematology in Lower and Middle Income CountriesDavid J Roberts, Nichola Cooper, Imelda Bates
European Journal of Internal Medicine|October 3, 2018
Management of immune thrombocytopenia in elderly patientsElisa Lucchini, Renato Fanin, Nichola Cooper, et al.
British Journal of Haematology|September 22, 2023
The role of genetics in refractory immune thrombocytopeniaJames L Zehnder, James B Bussel, Nichola Cooper
British Journal of Haematology|May 15, 2009
Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulinNichola Cooper, E Graham Davies, Adrian J Thrasher
British Journal of Haematology|August 9, 2011
The importance of developing world haematologyNichola Cooper, Daniel Hart, Imelda Bates, et al.
Annals of Hematology|July 26, 2021
Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopeniaJohn D Grainger, Thomas Kühne, Jane Hippenmeyer, et al.
American Journal of Hematology|May 19, 2020
"ITP" is not always immune thrombocytopeniaAlexandra Holyome, Nichola Cooper, Amrana Qureshi, et al.
Current Opinion in Hematology|September 28, 2007
Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?Nichola Cooper, Maria Laura Evangelista, Sergio Amadori, et al.
British Journal of Haematology|July 1, 2021
Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant settingMaria Gabelli, Christine Ademokun, Nichola Cooper, et al.
Pageof 15

Showing results (21-30 of 141) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|February 11, 2011
Safety of recombinant activated factor VII in randomized clinical trialsAmit Patel, Nichola Cooper, Michael A Laffan
British Journal of Haematology|April 4, 2017
Haematology in Lower and Middle Income CountriesDavid J Roberts, Nichola Cooper, Imelda Bates
European Journal of Internal Medicine|October 3, 2018
Management of immune thrombocytopenia in elderly patientsElisa Lucchini, Renato Fanin, Nichola Cooper, et al.
British Journal of Haematology|September 22, 2023
The role of genetics in refractory immune thrombocytopeniaJames L Zehnder, James B Bussel, Nichola Cooper
British Journal of Haematology|May 15, 2009
Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulinNichola Cooper, E Graham Davies, Adrian J Thrasher
British Journal of Haematology|August 9, 2011
The importance of developing world haematologyNichola Cooper, Daniel Hart, Imelda Bates, et al.
Annals of Hematology|July 26, 2021
Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopeniaJohn D Grainger, Thomas Kühne, Jane Hippenmeyer, et al.
American Journal of Hematology|May 19, 2020
"ITP" is not always immune thrombocytopeniaAlexandra Holyome, Nichola Cooper, Amrana Qureshi, et al.
Current Opinion in Hematology|September 28, 2007
Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?Nichola Cooper, Maria Laura Evangelista, Sergio Amadori, et al.
British Journal of Haematology|July 1, 2021
Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant settingMaria Gabelli, Christine Ademokun, Nichola Cooper, et al.
Pageof 15